Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Contrast Enhanced Ultrasonography (CEUS) of Patients With Crohn's Disease

This study has been terminated.
(Did not get enough patients)
University of Bergen
Information provided by (Responsible Party):
Haukeland University Hospital Identifier:
First received: February 23, 2010
Last updated: January 25, 2016
Last verified: January 2016
The purpose of this study is investigate if high frequency sonography and contrast enhanced sonography can be used to predict remission in patients with deterioration of Crohn's disease treated with steroids or tumor necrosis factor (TNF) alfa inhibitors.

Crohn's Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: High Frequency Ultrasound and Contrast Enhanced Ultrasound of Patients Treated for Deterioration of Crohn's Disease

Resource links provided by NLM:

Further study details as provided by Haukeland University Hospital:

Primary Outcome Measures:
  • Remission defined by Crohns disease activity index (CDAI)<150 [ Time Frame: 52 weeks from inclusion ]

Secondary Outcome Measures:
  • Surgical treatment for Crohn's disease during follow up. (Surgery for perianal disease not included.) [ Time Frame: 52 weeks ]
  • Mucosal healing on ileocolonoscopy. Defined by Simple Endoscopic Index for Crohn's disease (SES-CD) [ Time Frame: 12 weeks ]

Biospecimen Retention:   Samples With DNA
Mucosal biopsies from the colon and terminal ileum.

Enrollment: 20
Study Start Date: November 2009
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Deterioration, Crohn's disease
Patients > 18 years old with a deterioration of Crohn's disease defined by CDAI >150 and requiring treatment with systemic steroids or TNF alfa inhibitors


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Patients treated for deterioration of Crohn's disease either in the out patient clinic or the medical ward of Haukeland University Hospital.

Inclusion Criteria:

  • Deterioration of Crohn's disease
  • CDAI>150
  • Treated with systemic steroids or TNF alfa inhibitors
  • Lesion found on ultrasound

Exclusion Criteria:

  • Disease location not reachable with ileocolonoscopy
  • Pregnancy
  • Acute coronary disease
  • Unstable coronary disease
  • Previous allergic reaction to SonoVue or its components
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01074580

Department of Medicine, Haukeland University Hospital
Bergen, Hordaland, Norway, 5021
Sponsors and Collaborators
Haukeland University Hospital
University of Bergen
Study Director: Trygve Hausken, PhD Nastional Center of Gastroenterological Ultrasonography, Haukeland University Hospital, Bergen, Norway
  More Information

Responsible Party: Haukeland University Hospital Identifier: NCT01074580     History of Changes
Other Study ID Numbers: 22209
Study First Received: February 23, 2010
Last Updated: January 25, 2016

Keywords provided by Haukeland University Hospital:
Crohn's disease
contrast enhanced ultrasound

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases processed this record on April 24, 2017